<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282785</url>
  </required_header>
  <id_info>
    <org_study_id>ABABS001</org_study_id>
    <nct_id>NCT04282785</nct_id>
  </id_info>
  <brief_title>Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy</brief_title>
  <official_title>Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective clinical study will investigate if antibiotic concentrations in patients
      with severe infections can be monitored by the UV-VIS spectroscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early and correct antibiotic treatment has a fundamental effect on survival in severe
      infections, and to prevent resistance development. However, it is unclear if this is achieved
      in severely ill patients with severe infections. Underdosing of antibiotics leads to lack of
      effect against bacteria and selection of multi-resistant strains. Overdosing of antibiotics
      increases the risk of toxicity and poses a threat to the environment. Currently there is no
      method for rapid or bedside determination of antibiotic concentration in routine health care.

      Pharmacolog AB, an Uppsala Med-tech company, has developed a technology and a product
      DrugLog® based on absorption spectroscopy in ultraviolet - visible (UV-VIS) frequencies that
      can measure the concentration of antibiotics.

      The goal of this project is to investigate if antibiotic concentrations in patients could be
      monitored by the UV-VIS spectroscopy.

      In a prospective observational study, blood samples from 100 patients with severe infections
      treated with cefotaxime, piperacillin/tazobactam or meropenem will be measured by UV-VIS
      spectroscopy as well as with the golden standard, High-performance liquid chromatography-mass
      spectrometry (HPLC-MS) at Klinisk farmakologi, Huddinge hospital, Stockholm.

      After informed consent, samples will be taken prior to antibiotic treatment and three times
      thereafter. Demographic and clinical data will be registered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Agreement in antibiotic concentration in blood with UV-VIS technicue vs. HPLC-MS expressed bias (limits of agreements) in a Bland Altman plot.</measure>
    <time_frame>0-48 hours of antibiotic treatment.</time_frame>
    <description>The antibiotic concentration will be calculated from the change in from transmittance measured with UV-VIS spectroscopy technique and compared with change antibiotic concentration measured with HPLC-MS using linear regression and Bland-Altman plots. The endpoint will be presented as bias (limits of agreement).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement in antibiotic concentration change in blood after antibiotic administration with UV-VIS technique vs HPLC-MS</measure>
    <time_frame>Blood samples will be taken just before the first dose of antibiotic, two hours after the first dose of antibiotic, just before the second dose and two hours after the second dose.</time_frame>
    <description>The antibiotic concentration will be calculated from the change in from transmittance measured with UV-VIS spectroscopy technique and compared with change antibiotic concentration measured with HPLC-MS using linear regression and Bland-Altman plots. The endpoint will be presented as bias (limits of agreement).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>Cohort of patients with severe infections</arm_group_label>
    <description>Patients with severe infections admitted to the Uppsala University Hospital and gets treated with either Piperacillin-Tazobactam, Meropenem or Cefotaxim</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Concentration monitoring of antibiotics in plasma</intervention_name>
    <description>Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.</description>
    <arm_group_label>Cohort of patients with severe infections</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All Patients with suspected infection that is prescribed with antibiotics (cefotaxime,
        piperacillin/tazobactam or meropenem) that is hospitalized and admitted to the infection
        ward, Intermediate ward or ICU.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 18 years old

          -  Suspected infection where treatment with cefotaxime, piperacillin/tazobactam or
             meropenem is prescribed

        Exclusion Criteria:

          -  Pregnancy

          -  Intermittent haemodialysis

          -  Patient with limited treatment decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miklos Lipcsey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of surgical science, Uppsala University hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miklos Lipcsey</last_name>
    <phone>+46186110000</phone>
    <email>Miklos.Lipcsey@surgsci.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Skorup</last_name>
    <phone>+46186110000</phone>
    <email>paul.skorup@medsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uppsala university hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Lipcsey, MDPhD</last_name>
      <phone>+46701756419</phone>
      <email>miklos.lipcsey@surgsci.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Paul Skorup</last_name>
      <email>paul.skorup@medsci.uu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parrillo JE, Skrobik Y, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009 May;35(5):871-81. doi: 10.1007/s00134-008-1367-2. Epub 2008 Dec 9.</citation>
    <PMID>19066848</PMID>
  </reference>
  <reference>
    <citation>Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 2009 May;33(5):432-6. doi: 10.1016/j.ijantimicag.2008.10.005. Epub 2008 Dec 16.</citation>
    <PMID>19091521</PMID>
  </reference>
  <reference>
    <citation>Fuchs M, Sanyal AJ. Sepsis and cholestasis. Clin Liver Dis. 2008 Feb;12(1):151-72, ix. doi: 10.1016/j.cld.2007.11.002. Review.</citation>
    <PMID>18242502</PMID>
  </reference>
  <reference>
    <citation>Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, Perrotin D, Dequin PF, Le Guellec C. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol. 2011 Nov;72(5):758-67. doi: 10.1111/j.1365-2125.2011.04005.x.</citation>
    <PMID>21545483</PMID>
  </reference>
  <reference>
    <citation>Green L, Dick JD, Goldberger SP, Angelopulos CM. Prolonged elimination of piperacillin in a patient with renal and liver failure. Drug Intell Clin Pharm. 1985 Jun;19(6):427-9.</citation>
    <PMID>4006736</PMID>
  </reference>
  <reference>
    <citation>SAFE Study Investigators, Finfer S, McEvoy S, Bellomo R, McArthur C, Myburgh J, Norton R. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011 Jan;37(1):86-96. doi: 10.1007/s00134-010-2039-6. Epub 2010 Oct 6.</citation>
    <PMID>20924555</PMID>
  </reference>
  <reference>
    <citation>Jager NG, van Hest RM, Lipman J, Taccone FS, Roberts JA. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol. 2016 Jul;9(7):961-79. doi: 10.1586/17512433.2016.1172209. Epub 2016 Apr 15. Review.</citation>
    <PMID>27018631</PMID>
  </reference>
  <reference>
    <citation>Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother. 1993 Nov;32 Suppl B:117-22.</citation>
    <PMID>8150754</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96.</citation>
    <PMID>16625125</PMID>
  </reference>
  <reference>
    <citation>Lau AH, Kronfol NO, John E. Increased vancomycin elimination with continuous hemofiltration. ASAIO Trans. 1987 Jul-Sep;33(3):772-4.</citation>
    <PMID>3676016</PMID>
  </reference>
  <reference>
    <citation>Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, Peterson MW, Rock P, Hyzy RC, Anzueto A, Truwit JD; National Institutes of Health National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med. 2011 Dec;39(12):2665-71. doi: 10.1097/CCM.0b013e318228234b.</citation>
    <PMID>21785346</PMID>
  </reference>
  <reference>
    <citation>Macnab MS, Macrae DJ, Guy E, Grant IS, Feely J. Profound reduction in morphine clearance and liver blood flow in shock. Intensive Care Med. 1986;12(5):366-9.</citation>
    <PMID>3771915</PMID>
  </reference>
  <reference>
    <citation>Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R; RENAL Replacement Therapy Study Investigators. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012 May;40(5):1523-8. doi: 10.1097/CCM.0b013e318241e553.</citation>
    <PMID>22511133</PMID>
  </reference>
  <reference>
    <citation>Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.</citation>
    <PMID>24429437</PMID>
  </reference>
  <reference>
    <citation>Salam FA, Shoaib MH, Yousuf RI, Sultan F, Khan MA, Manzoor S. Simultaneous quantitation of Ofloxacin, Fexofenadine HCl and Diclofenac Potassium in affixed dose combinative formulation by HPLC-UV method. Pak J Pharm Sci. 2015 Nov;28(6):1979-84.</citation>
    <PMID>26639475</PMID>
  </reference>
  <reference>
    <citation>Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol. 2015 Oct;24:1-6. doi: 10.1016/j.coph.2015.06.002. Epub 2015 Jun 25. Review.</citation>
    <PMID>26119486</PMID>
  </reference>
  <reference>
    <citation>Wen X, Peng Z, Kellum JA. Pathogenesis of acute kidney injury: effects of remote tissue damage on the kidney. Contrib Nephrol. 2011;174:129-137. doi: 10.1159/000329382. Epub 2011 Sep 9. Review.</citation>
    <PMID>21921617</PMID>
  </reference>
  <reference>
    <citation>White LE, Hassoun HT, Bihorac A, Moore LJ, Sailors RM, McKinley BA, Valdivia A, Moore FA. Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis. J Trauma Acute Care Surg. 2013 Sep;75(3):432-8. doi: 10.1097/TA.0b013e31829de6cd.</citation>
    <PMID>24089113</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323-9. doi: 10.1001/jama.2009.1754.</citation>
    <PMID>19952319</PMID>
  </reference>
  <reference>
    <citation>Wolff F, Deprez G, Seyler L, Taccone F, Hites M, Gulbis B, Vincent JL, Jacobs F, Cotton F. Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta. 2013 Jan 15;103:153-60. doi: 10.1016/j.talanta.2012.10.024. Epub 2012 Oct 18.</citation>
    <PMID>23200371</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meropenem</keyword>
  <keyword>cefotaxime</keyword>
  <keyword>piperacillin/tazobactam</keyword>
  <keyword>Drug Monitoring</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

